Case Report

Epstein Barré Virus-Negative Diffuse Large B-Cell Lymphoma in an HIV-Infected Man with a Durable Complete Remission on Highly Active Antiretroviral Therapy Alone

Authors: Anita Koszyk-Szewczyk, MD, Michael Bayerl, MD, John Zurlo, MD, Joseph J. Drabick, MD, FACP

Abstract

We report a unique case of a human immunodeficiency virus (HIV)-infected man with Epstein-Barré virus (EBV) negative diffuse large B-cell lymphoma (DLBCL) that responded solely to highly active antiretroviral therapy (HAART). Our patient presented with a retroperitoneal mass, high viral load, CD4 288 and began therapy with HAART with marked improvement of symptoms. The patient declined chemotherapy since he felt better after HAART, and rescanning at that time demonstrated marked improvement of the lymphoma on HAART alone. Viral load became undetectable, CD4 450 by 8 weeks. By 6 months, the patient had a complete remission verified by positron emission tomography/computed tomography (PET/CT) and has remained in remission to date on HAART alone. We postulate that HIV infection directly precipitated the lymphoma.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus–related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med 1993;95:188–196.
 
2. Rabkin C. Epidemiology of AIDS-related malignancies. Curr Opin Oncol 1994;6:492–496.
 
3. Kirk O, Pedersen C, Cozzi-Lepri A; EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406–3412.
 
4. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2000;37:1320–1324.
 
5. O'Connor PG, Scadden DT. Aids oncology. Infect Dis Clin North Am 2000;14:1–13.
 
6. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007;60:1365–1372.
 
7. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus–related non-hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556–1564.
 
8. Tirelli U, Errante D, Oksenhendler E, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol 1992;3:843–847.
 
9. Tirelli U, Spina M, Gabarre J, et al. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors [abstract 91]. J Acquir Immune Defic Syndr 1999;21(suppl A):A32.
 
10. Tirelli U, Spina M, Gaidano G, et al. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000;14:1675–1688.
 
11. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus–related, non-Hodgkin's lymphoma. Cancer 2001;91:155–163.
 
12. Snedecor GW, Cochran WG. Statistical Methods. Ames, IA, Iowa State University Press, 1980.
 
13. Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men: relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984;311:565–570.
 
14. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719–724.
 
15. Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and azidothymidine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991;266:84–88.
 
16. Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus–related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466–2472.
 
17. Cavanna L, Pagani R, Seghini P, et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol 2008;6:35.
 
18. Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy post highly active antiretroviral therapy era? Hematol Oncol 2004;22:111–120.
 
19. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–116.
 
20. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000;18:10–18.
 
21. Zanussi S, Simonelli C, D'Andrea M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996;12:1703–1707.
 
22. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000;14:133–140.
 
23. Rabkin CS, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1- infected individuals. Blood 1999;93:1838–1842.
 
24. Przybylski GK, Goldman J, Ng VL, et al. Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood 1996;88:4620–4629.
25. Jarrett RF. Viruses and lymphoma/leukaemia. J Pathol 2006;208:176–186.
 
26. Knowles D. Etiology and pathogenesis of AIDS-related non-Hodgkin's Lymphoma. Hematol Oncol Clin North Am 2003;17:785–820.
 
27. Herndier BG, Shiramizu BT, Jewett NE, et al. Acquired immunodeficiency syndrome associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. Blood 1992;79:1768–1774.
 
28. Kundu RK, Sangiorgi F, Wu LY, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood 1999;94:275–282.
 
29. McClain KL. Epstein-Barr virus and HIV-AIDS-associated diseases. Biomed Pharmacother 2001;55:348–352.
 
30. Ioachim HL, Antonescu C, Giancotti F, et al. EBV-associated primary lymphomas in salivary glands of HIV-infected patients. Pathol Res Pract. 1998;194:87–95.
 
31. Andonopoulos AP, Tiniakou M, Melachrinou M, et al. Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma. Rev Rhum Engl Ed 1997;64:287–292.
 
32. Lehours P, Mégraud F. Helicobacter pylori infection and gastric MALT lymphoma. Rocz Akad Med Bialymst 2005;50:54–61.
 
33. Thiede C, Wündisch T, Alpen B, et al; German MALT Lymphoma Study Group. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001;19:1600–1609.
 
34. Morgner A, Bayerdörffer E, Neubauer A, et al. Gastric MALT lymphoma and its relationship to Helicobacter pylori infection: management and pathogenesis of the disease. Microsc Res Tech 2000;48:349–356.
 
35. Kütting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997;36:311–314.
 
36. Amengual JE, Zhang X, Ibrahim S, et al. Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone. Blood 2008; 112:4359–4360.